Abstract
Health technology assessment (HTA) refers to a multidisciplinary process to scientifically analyze, summarize, and understand information about medical, social, economic, and ethical issues related to the application of a health technology. From a science point of view, the method of assessment must be systematic, transparent, and statistically unbiased.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
International Network of Agencies for Health Technology Assessment (2009) HTA Resources. http://www.inahta.org/. Accessed 30 Mar 2016
Health Technology Assessment International. What is HTA? http://www.htai.org/. Accessed 30 Mar 2016
Towse A, Devlin N, Hawe E, Garrison L (2011) The evolution of HTA in emerging market health care systems: analysis to support a policy response. OHE Consulting Report for PhRMA, Office of Health Economics
Pearson SD, Rawlins MD (2005) Quality, innovation, and value for money: NICE and the British National Health Service. JAMA 294(20):2618–2622
Rawlins MD (2005) 5 NICE years. Lancet 365(9462):904–908
Japan Revitalization Strategy revised in 2014. Introduction of cost-effectiveness analysis in coverage decisions for innovative health technology. p 98. http://www.kantei.go.jp/jp/singi/keizaisaisei/pdt/honbun2JP.pdf. Accessed 30 Mar 2016
Central Social Insurance Medical Council Special Committee on Cost-Effectiveness. Proceedings of the 32th meeting. http://www.mhlw.go.jp/stf/shingi2/0000107118.html. Accessed 30 May 2016
Sackett DL, Straus SE, Richardson WS et al (2000) Evidence-based medicine: how to practice and teach EBM. Churchill Livingstone, New York
Brown MM, Brown GC, Sharma S (2005) Evidence-based to value-based medicine. American Medical Association, Chicago
Bootman JL, Townsend RJ, McGhan WF (2004) Principles of pharmacoeconomics, 3rd edn. Harvey Whitney Books, Cincinnati, OH
Pharmaceutical and Medical Device Regulatory Science Society of Japan (ed) 2014 Introduction to health technology assessment: toward a comprehensive understanding of cost-effectiveness. Pharmaceutical and Medical Device Regulatory Science Society of Japan, Tokyo
Cohen JT, Neumann PJ, Weinstein MC (2008) Does preventive care save money? Health economics and the presidential candidates. N Engl J Med 358(7):661–663
Institute of Medicine (2009) Initial national priorities for comparative effectiveness research. National Academies Press, Washington, DC. http://www.nationalacademies.org/hmd/Reports.aspx?searchQuery=CER. Accessed 30 Mar 2016
American College of Physicians (2008) Information on cost-effectiveness: an essential product of a national comparative effectiveness program. Ann Intern Med 148(12):956–961
Chalkidou K, Tunis S, Lopert R et al (2009) Comparative effectiveness research and evidence-based health policy: experience from four countries. Milbank Q 87(2):339–367
Luce BR, Drummond M, Jonsson B et al (2010) EBM, HTA, and CER: clearing the confusion. Milbank Q 88(2):256–276
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Kamae, I. (2019). Basics to Know. In: Health Technology Assessment in Japan. Adis, Singapore. https://doi.org/10.1007/978-981-13-5793-0_1
Download citation
DOI: https://doi.org/10.1007/978-981-13-5793-0_1
Published:
Publisher Name: Adis, Singapore
Print ISBN: 978-981-13-5792-3
Online ISBN: 978-981-13-5793-0
eBook Packages: MedicineMedicine (R0)